|Reference : Immunosuppression in Pancreas Transplantation The Euro SPK Trials and Beyond|
|Scientific journals : Article|
|Human health sciences : Surgery|
|Immunosuppression in Pancreas Transplantation The Euro SPK Trials and Beyond|
|Malaise, J. [> >]|
|De Roover, Arnaud [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]|
|Squifflet, Jean-Paul [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]|
|Land, W. [> >]|
|europe SPK study group [> >]|
|Acta Chirurgica Belgica|
|Acta Medica Belgica|
|[en] Pancreas Transplantation ; immunosuppression|
|[en] The Immunosuppression in Pancreas Transplantation was historically based on the fact that the pancreas is an
extremely immunogenic organ. Quadruple drug therapy with polyclonal or monoclonal antibodies induction was the
mainstay therapy since the introduction of Cyclosporine A.
In the modern era of Immunosuppression, Mycophenolate Mofetil replaced Azathioprine while Tacrolimus-another potent
calcineurin inhibitor-had-and still has-a difficult challenge to replaced Cyclosporine A, due to its potential diabetogenic
effect. Thanks to the first two EuroSPK studies which prospectively tried to answer several questions in that field.
But, the future challenge will be in understanding the impact of innate immunity and ischemic reperfusion injuries on
the long term graft function. Hopefully, new drugs will be available and tested to block unspecific deleterious reactions
to attenuate the proinflammatory response. It will be the aim of the third Euro SPK Stud
|Professionals ; Students ; General public|
|File(s) associated to this reference|
All documents in ORBi are protected by a user license.